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OBJECTIVE — Cardiovascular disease (CVD) is prevalent and expensive. While many inter-
ventions are recommended to prevent CVD, the potential effects of a comprehensive set of
prevention activities on CVD morbidity, mortality, and costs have never been evaluated. We
therefore determined the effects of 11 nationally recommended prevention activities on CVD-
related morbidity, mortality, and costs in the U.S.
RESEARCH DESIGN AND METHODS — We used person-speciﬁc data from a repre-
sentative sample of the U.S. population (National Health and Nutrition Education Survey IV) to
determine the number and characteristics of adults aged 20–80 years in the U.S. today who are
candidates for different prevention activities related to CVD. We used the Archimedes model to
create a simulated population that matched the real U.S. population, person by person. We then
used the model to simulate a series of clinical trials that examined the effects over the next 30
years of applying each prevention activity one by one, or altogether, to those who are candidates
for the various activities and compared the health outcomes, quality of life, and direct medical
costs to current levels of prevention and care. We did this under two sets of assumptions about
performance and compliance: 100% success for each activity and lower levels of success con-
sidered aggressive but still feasible.
RESULTS — Approximately 78% of adults aged 20–80 years alive today in the U.S. are
candidates for at least one prevention activity. If everyone received the activities for which they
are eligible, myocardial infarctions and strokes would be reduced by 63% and 31%, respec-
tively. If more feasible levels of performance are assumed, myocardial infarctions and strokes
would be reduced 36% and 20%, respectively. Implementation of all prevention activities
would add 221 million life-years and 244 million quality-adjusted life-years to the U.S. adult
population over the coming 30 years, or an average of 1.3 years of life expectancy for all adults.
Of the speciﬁc prevention activities, the greatest beneﬁts to the U.S. population come from
providing aspirin to high-risk individuals, controlling pre-diabetes, weight reduction in obese
individuals, lowering blood pressure in people with diabetes, and lowering LDL cholesterol in
peoplewithexistingcoronaryarterydisease(CAD).Ascurrentlydeliveredandatcurrentprices,
most prevention activities are expensive when considering direct medical costs; smoking cessa-
tion is the only prevention strategy that is cost-saving over 30 years.
CONCLUSIONS — Aggressiveapplicationofnationallyrecommendedpreventionactivities
could prevent a high proportion of the CAD events and strokes that are otherwise expected to
occurinadultsintheU.S.today.However,astheyarecurrentlydelivered,mostoftheprevention
activities will substantially increase costs. If preventive strategies are to achieve their full poten-
tial, ways must be found to reduce the costs and deliver prevention activities more efﬁciently.
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T
hree chronic diseases—cancer,
cardiovascular disease (CVD), and
diabetes—are responsible for a
majority of the morbidity, mortality,
and health care costs in the U.S (1–8).
Tohelpreducethetollofthesediseases,
the American Cancer Society, American
Diabetes Association, and American
Heart Association have recommended a
variety of prevention activities (8). Each
is supported by good evidence of effec-
tiveness (8–16) and widely accepted.
However,despitethissupport,thereare
large gaps in how well they are applied,
and a high proportion of the U.S. pop-
ulation is not receiving prevention ac-
tivities from which they would beneﬁt
(17–21).
To stimulate greater attention to pre-
ventionandtohelpphysiciansandhealth
care delivery organizations implement
prevention activities, it is important to
know the answers to several questions.
First, how many people alive today are
candidates for at least one prevention ac-
tivity? Second, how much of the morbid-
ity, mortality, and cost of these diseases is
potentially preventable? Stated another
way, by how much could the burden of
chronic diseases be reduced if prevention
activities were applied with 100% perfor-
mance, compliance, and effectiveness?
Third, what could realistically be accom-
plished if patients, physicians, and health
plans throughout the country pursued
prevention at levels of performance and
complianceachievedbythemostsuccess-
fulorganizations?Fourth,howdothevar-
ious prevention activities compare?
Which are the most important in terms of
theirpotentialeffectsonhealthoutcomes,
costs, and cost-effectiveness? Fifth, what
does prevention cost? If pursued at max-
imumfeasibilitylevels,wouldthecostsbe
offsetbythesavings?Finally,whatarethe
main factors that determine the cost-
effectiveness of a prevention activity, and
what are the best ways to make preven-
tion more attractive ﬁnancially? This re-
port offers answers to these questions for
the prevention of CVD.
RESEARCH DESIGN AND
METHODS
Overview
Ideally, the answers to the above ques-
tionswouldbeobtainedbyexaminingthe
results of clinical trials. While there are
studies that document that each of the
prevention activities is effective, none of
the existing studies addresses a represen-
tative sample of the U.S. population, ad-
dresses speciﬁc treatment goals that are
being recommended, or includes repre-
sentativeU.S.costs.Furthermore,itisnot
possible to conduct the needed trials
because of the large number of activi-
ties, long time horizons, large numbers
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such research.
Lacking clinical trials, the only alter-
nativeistouseamathematicalmodel.For
this analysis, we selected the Archimedes
model from other available mathematical
models because of its ability to simulate
the U.S. population at a person-speciﬁc
level, its ability to simulate current pat-
terns of care, its inclusion of all the rele-
vant diseases and prevention activities in
asingleintegratedmodel,itsabilitytoan-
alyze the prevention activities precisely as
they are recommended, its ability to ad-
dress all the questions of interest using a
consistent methodology, and its demon-
strated accuracy in reproducing the trials
thatdocumenttheeffectivenessofeachof
the recommended interventions.
Archimedes model
The Archimedes model is a person-by-
person, object-by-object, large-scale sim-
ulation model of physiology, disease, and
health care systems written at a high level
of detail using object-oriented program-
ming and run on a distributed computing
network(22–26).Thecoreofthemodelis
asetofordinaryanddifferentialequations
that represent the physiological pathways
pertinent to diseases and their complica-
tions. Currently, the model includes cor-
onary artery disease (CAD), stroke,
diabetesanditscomplications,congestive
heart failure, obesity, smoking, asthma,
and the metabolic syndrome in a single
integrated model. The model also in-
cludes aspects of diseases and health care
systems needed to analyze downstream
clinical events, utilization, and costs in-
cluding signs and symptoms; patient en-
counterswiththehealthcaresystem(e.g.,
emergency room visits, ofﬁce visits, and
admissions); protocols and guidelines;
tests and treatments; patient adherence to
treatment recommendations; and clinical
eventsthataffectlogistics,utilization,and
ﬁnancial costs.
Physiological variables that are con-
tinuous in reality are continuous in the
model (e.g., blood pressure and glucose
levels), time is continuous, symptoms are
drivenbyunderlyingvariables,testsmea-
sure underlying variables, treatments af-
fect underlying variables, and outcomes
are determined by the progression of the
variables.
Costs related to the conditions that
areinthemodelarecalculatedbytracking
all the pertinent cost-generating events
using micro-costing methods (32). Costs
of other conditions that are not currently
calculated in the model, such as cancer or
osteoporosis (“unrelated costs”) (32), are
addedseparatelyasafunctionofvariables
that are in the model (e.g., age, sex,
weight, and disease states).
The model uses person-speciﬁc data
from real populations (e.g., the National
Health and Nutrition Education Survey
[NHANES]) to create simulated popula-
tionsthatmatchtherealpopulations,per-
son by person. Each individual can be
matched to variables such as demograph-
ics, risk factors, biological variables, cur-
rent and past medical histories, and
current treatments. The methods for cre-
ating the copies of real people preserve
the distributions and correlations of all
the important risk factors and biological
variables.
The model’s accuracy is checked by
usingittosimulateclinicaltrialsthathave
been conducted in the real world and
comparing the predicted results with the
real results. This has been done success-
fully for several hundred treatments and
outcomes in 48 randomized controlled
trials thus far. Methods and results for the
ﬁrst 74 validation exercises involving 18
trials have been published (24). More
than half of those (10 of 18 trials) were
independent validations (33) in which no
results in the trial were used to build or
modify the model. More information
about the Archimedes model, including
additionaldetailsabouttheequationsand
sources, is available elsewhere (26).
The current study
Forthisstudy,weanalyzed11prevention
activities relating to CVD and combina-
tionsoftheseactivities(Table1).Wecon-
ducted the analysis in three steps. First,
we used person-speciﬁc data from the
most current NHANES (1998–2004) to
determinethecharacteristics(includingsex
and ethnicity), risk factors, and current lev-
els of prevention in the U.S. population
(34). We also used the NHANES data to
create simulated populations that matched
the real U.S. population.
Second, we created a care delivery
setting that could serve as a representa-
Table 1—Interventions studied
Intervention
Total eligible
population
1,000 (%)
Treatment
goals
Feasible
performance
(% achieved)*
Baseline (without interventions) 200,000 (100) — —
Provide aspirin if 10-year MI risk 10% 12,315 (6.2)† 81 mg aspirin/day 50
Lower LDL cholesterol to 160 mg/dl in low-risk individuals‡ 15,445 (7.7) 160 mg/dl 75
Lower LDL cholesterol to 130 mg/dl in high-risk individuals§ 17,857 (8.9) 130 mg/dl 70
Lower LDL cholesterol to 100 mg/dl in people with CAD 3,212 (1.8) 100 mg/dl 70
Lower blood pressure to 140/90 mmHg in nondiabetic individuals 30,820 (15.4) 140/90 mmHg 75
Lower A1C to 7.0% in diabetic individuals 5,739 (2.9) 7.0% 60
Lower blood pressure to 130/80 mmHg in diabetic individuals 11,498 (5.8) 130/80 mmHg 60
Lower LDL cholesterol to 100 mg/dl in diabetic individuals 13,000 (6.5) 100 mg/dl 65
Reduce FPG to 110 mg/dl 16,392 (8.2) FPG 110 mg/dl 60
Smoking cessation 49,265 (24.6) Stop immediately 30
Reduce weight to BMI 30 kg/m
2 60,257 (30.1) BMI 30 kg/m
2 20
Treatmentgoalswereobtainedfrompublishedguidelines(8,27–31).*Derivedfromrefs.37–43anddeﬁnedasaperformancelevelbyhealthplansorinlargehealth
care systems that has been achieved in a clinical setting. †Assumes that 70% of the population at risk is already taking aspirin (36), leaving 12,315 million (6.2%)
stilleligible.‡Lowriskdeﬁnedashaving0or1ofthefollowingriskfactors:bloodpressure140/90mmHg,HDLcholesterol40mg/dl,familyhistoryofMIbefore
age 55 years, male 45 or female 55 years of age. §High risk deﬁned as having two or more of the risk factors deﬁned in the above footnote. FPG, fasting plasma
glucose.
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ered in the U.S. We modiﬁed different
aspects of the care setting through sensi-
tivity analysis. For the representative set-
ting, we based the use of prevention
activities and degree of control of risk fac-
tors on the practices and success rates in
the NHANES population. We based the
treatment of symptoms and complica-
tions (e.g., management of diabetes and
CVD) on national guidelines. We based
the costs of drugs on information pro-
vided by drugstore.com and the cost of
general medical care (e.g., emergency vis-
its, ofﬁce visits and admissions, and pro-
cedures) on costs experienced by Kaiser
Permanente Southern California or from
the literature (35). The costs of the pre-
vention activities assumed for the refer-
ence case are given in Table 2. For the
reference case, the costs of unrelated care
and extra costs for the last year of life (be-
yond the costs related to the diseases cal-
culated explicitly in the model) were set
to zero. Different assumptions about the
costs of prevention activities, general
medical costs, and unrelated medical
costs were all studied through sensitivity
analysis.
The third step was to use the simu-
lated populations and simulated care de-
livery setting to conduct 13 simulated
clinical trials. Eleven of the trials ad-
dressed prevention activities, one by one
(Table 1). The other two trials addressed
the combination of all 11 activities, given
either with 100% performance and suc-
cessinreachingthetreatmenttargetsorat
more feasible levels. To the extent possi-
ble, the reference assumptions about fea-
sible levels of performance (Table 1) were
based on the levels of success that have
been achieved in various clinical settings
(36–42). Uncertainty about feasible per-
formance levels was studied through sen-
sitivity analysis. Additional simulated
trials were conducted to study the sensi-
tivity of the results to bundling of preven-
tion services.
Analogous to the treatment arms of a
clinical trial, the simulated population
createdforeachtrialwassubjectedtotwo
management protocols. One manage-
mentprotocolrepresented“currentcare”:
for each individual, we determined that
person’s current level of adoption of pre-
vention(e.g.,smokinghabits,weight,and
blood pressure) and assumed that the
level of care responsible for that level of
prevention would continue. Behaviors
and physiological variables would be al-
lowedtoprogressnaturallyasoccurswith
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1688 DIABETES CARE, VOLUME 31, NUMBER 8, AUGUST 2008age but with no changes in any aspects of
theircarerelevanttothepreventionactiv-
itieslistedinTable1.Inthesecurrentcare
treatment arms, individuals were given
additional treatments (beyond their cur-
rent levels of prevention care) only if they
developed symptoms, in which case the
model assumed they sought care, or if clin-
ical events such as heart attacks occurred.
Eachoftheﬁrst11“one-by-one”trials
alsohada“prevention”arminwhichpeo-
ple who were candidates for the applica-
ble prevention activity were identiﬁed
and treated to a level slightly (2–3%)
below whatever target was speciﬁed for
the applicable prevention activity. For
these treatment arms, each individual in
the simulated population was examined
at the initiation of the trial and annually
thereafter to determine whether he or she
was a candidate for treatment according
to whatever prevention activity was the
subject of the trial. If a person met the
criteria for the applicable prevention ac-
tivity, then he or she would be treated to
slightlybelowthecorrespondingtargetof
that prevention activity. For example, if
the trial was to estimate the effect of con-
trolling A1C in people with currently un-
controlled diabetes, then each individual
in the simulated population was given a
simulated examination at the start of the
trial to determine whether he or she had a
diagnosis of diabetes and an A1C level
7%. If so, that person was treated to
reduce their A1C level to 6.8%. Everyone
with a condition was then reexamined at
annual intervals to determine whether
their A1C levels had increased to 7%
and treated as needed to maintain A1C
levels 7%. People who were not candi-
dates for the applicable prevention activ-
ity at the start of the simulation were
followedannually(screened)toseeifthey
developed the condition in the interval
following the previous examination, and
if so, they were treated accordingly. The
cost of screening (i.e., ofﬁce visits and
tests) was not considered.
For each of these simulated trials, we
calculatedtheoutcomesundertwosetsof
assumptions about performance and
compliance. In the ﬁrst case, we analyzed
the outcomes that would occur if 100%
performance and compliance levels were
achieved. This trial was done to estimate
the maximum potential of prevention
achievable by the recommended activi-
ties. In the second case, we applied more
realistic, albeit aggressive, assumptions
about what might constitute levels of per-
formance that were feasible.
In addition to the one-by-one trials,
we created two simulated trials to esti-
mate the overall proportion of U.S. adults
who are candidates for any intervention
and the overall effect of providing all of
the prevention activities to anyone who
was a candidate for them. In one of these
trials, all people who were candidates for
any of the prevention activities were
treated with 100% performance and ef-
fectiveness. In the other, treatments were
delivered at the more feasible levels of
performance.
The sample size for each simulated
trial was 50,000. The results were then
scaledtotheU.S.adultpopulation,which
in 2005 was 200 million individuals.
Each trial was run for 30 years. All out-
comes were calculated continuously and
reported at annual intervals. For each
trial, we calculated a wide range of health
and economic outcomes. Here we report
the total number of myocardial infarc-
tions(MIs)(includingrepeatMIs),deaths
from coronary heart disease (CHD),
stroke, life-years, quality-adjusted life-
years (QALYs), cost of prevention activi-
ties,costofcareotherthantheprevention
activities,totalmedicalcosts,andcostper
QALY. Quality-of-life weights for the var-
ious clinical states and outcomes were
basedonasurveybySullivanandGhush-
chyan (43) and varied in the sensitivity
analysis. For calculating cost per QALY,
both costs and QALYs were discounted
3%, with different discount rates studied
through sensitivity analysis.
RESULTS— Of the 200 million peo-
ple in the U.S. today between the ages of
20 and 80 years, 156 million (78%)
meet the indications for at least one of the
prevention activities listed in Table 1. Ta-
ble 1 shows the numbers of people who
arecandidatesforeachparticularactivity;
they vary widely from 3.2 million indi-
viduals with CAD and LDL cholesterol
100 mg/dl (1.8% of adults) to 60 mil-
lion who have BMI 30 kg/m
2 (30.1% of
adults).
Table 3 shows the outcomes that can
be expected to occur in today’s adults (in-
dependent of sex or ethnicity) over the
next 30 years in the reference health care
setting if the use of prevention activities
continues at current levels (top row) and
the differences in outcomes that could
theoreticallybeachievedifpreventionac-
tivities were adopted with 100% perfor-
mance, compliance, and effectiveness.
These entries show the maximum poten-
tial of prevention in reducing clinical out-
comesofCVD.Forexample,ifprevention
continues at its current level, today’s
adults in the U.S. can expect to have 43
million MIs. If everyone adopted the
prevention activities for which they are
indicated, 27.4 million (63%) of
those MIs could be prevented. Other
columnsshowtheeffectsonstroke,life-
years, and QALYs.
Table 3 also shows the effects on
health care costs. The cost of caring for
CVD,diabetes,andCHDoverthecoming
30 years will be in the order of $9.5 tril-
lion. If all the recommended prevention
activities were applied with 100% suc-
cess, those costs would be reduced by
$904 billion, or almost 10%. However,
assuming the costs shown in Table 2, the
prevention activities themselves would
cost $8.5 trillion, offsetting the savings
by a factor of almost 10 and increasing
total medical costs by $7.6 trillion
(162%).
ThefarrightcolumnofTable3shows
the cost per QALY for each activity, as-
suming the reference costs in Table 2.
Smoking cessation is the only prevention
activity that can be expected to save
money, with the reductions in costs of
events more than offsetting the cost of the
smoking cessation programs. Next in
cost-effectiveness is the use of aspirin in
high-risk individuals. The effects on the
same outcomes using the maximum fea-
sible levels of prevention activities are
shown in Table 4.
Tables 3 and 4 show the effect of the
prevention activities on the U.S. popula-
tion as a whole. The effects take into ac-
count two factors, the number of people
who are candidates for a particular activ-
ity and the effect of the activity on those
who are candidates (i.e., effect/person 
number of people). Table 5 shows the
beneﬁts of prevention from the perspec-
tiveoftheindividualswhohaveparticular
risk factors. Each row shows the absolute
risk reduction or magnitude of the out-
comeover30yearsand,whereapplicable
(i.e., for MI and stroke), the number
needed to treat (NNT) to prevent one
event (30-year NNT). The table also
shows the increase in life expectancy,
with and without adjustment for quality
of life, for those who are candidates for
each activity. In some cases, the preven-
tion activity increases a person’s length of
life by an amount sufﬁcient to then in-
crease their risk of an adverse outcome
(e.g., A1C control on strokes).
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Table6summarizestheresultsofthesen-
sitivity analysis on cost per QALY for a
rangeofassumptionsaboutthecostofthe
prevention activities (20%), quality-of-
life weights (20%), unrelated medical
costs ($0 to $10,000/person/year), the
cost of dying ($0 to $40,000), the cost of
general medical care (20%), and dis-
countrates(0to6%).Themostimportant
determinants of the costs and cost per
QALY are the costs of the prevention ac-
tivities themselves (Table 7).
CONCLUSIONS — Our results lead
tosevenmainconclusions.First,thereare
large gaps in the application of preven-
tion, and thus large opportunities to re-
ducethemorbidityandmortalityofCVD.
Evenaftertakingintoaccountcurrentuse
ofpreventionactivities,thegreatmajority
ofadultsintheU.S.today(78%)stillmeet
the indications for at least 1 of the 11 pre-
vention activities we studied (Table 1). If
everypersoncouldreceivetheprevention
activities for which he or she is a candi-
date, MIs could be reduced 60% (from
43 million over 30 years to 16 mil-
lion), strokes could be reduced 30%
(from 33 million over 30 years to 23
million), and everyone’s life expectancies
couldbeincreasedanaverageof1.3years
and at a higher quality of life than cur-
rently experienced.
Second, even if the full potential of
preventioncannotbeachievedbecauseof
incomplete performance, compliance,
and effectiveness, the beneﬁts of aggres-
sive but feasible levels of performance are
still large. If performance levels could be
uniformly raised to those achieved by the
best health care delivery systems (Table
1), 36% of heart attacks and 20% of
strokes would be prevented, and life ex-
pectancies would be increased an average
of 0.7 years.
Third, the 11 prevention activities
vary widely in their effectiveness. Viewed
from the perspective of the U.S. popula-
tion as a whole (Table 3), the effects on
MIs range from prevention of 7.1 mil-
lion with weight control (BMI 30 kg/
m
2)t o1 million for cholesterol
treatmentinlow-riskpeople(LDLcholes-
terol160mg/dl).Fromtheperspectives
of individuals who are candidates for par-
ticular prevention activities (Table 5), the
beneﬁtsrangefromanabsolutereduction
of MI by 39% (30-year NNT  3) by con-
trol of LDL cholesterol 100 mg/dl in
people with established CAD to a de-
crease in the chance of an MI by an abso-
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LDL cholesterol in people who are at low
risk.
Fourth, as they are currently deliv-
ered, almost all of the prevention activi-
ties are expensive. If applied fully, using
current protocols and the reference as-
sumptions about costs (Table 2), they
would increase health care costs by
$8.5 trillion over 30 years (Table 3), or
$283 billion per year, or $1,700 per
person per year (data not shown). The
only cost-saving activity is smoking ces-
sation. Even if $600 is spent annually
(versus $350, as shown in Table 2) help-
ing a smoker quit, the savings from pre-
venting downstream CVD events more
than offset those costs, yielding a net sav-
ings. Aspirin use is relatively inexpensive
even if delivered with annual visits; net
costs are $50 billion over 30 years, or
$90 per candidate per year (Table 3).
Theother11activitiesincreasecostsfrom
$0.4 trillion to $1.8 trillion over 30 years
(Table 4).
Fifth, the activities vary widely in the
value they provide, as measured by cost
per QALY (Table 3). Only smoking cessa-
tion can be expected to save money over
the 30-year follow-up period, and even
that does not begin to save money until
after 8 years (data not shown). Aspirin for
high-risk people has a low cost per QALY
($3,000).Weightcontrolandcontrolof
pre-diabetes (fasting plasma glucose
110 mg/dl) have costs per QALY of
$18,000. The next ﬁve—blood pres-
sure control in diabetic and nondiabetic
people and LDL cholesterol control in
high-risk people and people with CAD or
diabetes—have cost per QALY between
$20,000 and the often-cited but arbitrary
threshold of $50,000. The lowest value is
provided by LDL cholesterol control in
low-risk people, $270,000/QALY. The
latter has important policy and clinical
implications, as it is currently one of the
most heavily promoted of all the preven-
tionactivities.Iftheobjectiveistoprevent
CVD, then smoking cessation, aspirin,
and control of pre-diabetes and weight
would be better uses of resources.
Sixth,the“importance”ofthepreven-
tion activities, in terms of MI and stroke
reduction, varies depending on whether
the beneﬁts are viewed from the perspec-
tiveofthepopulationasawhole(Tables3
and 4) or the individuals who are candi-
dates (Table 5). The former takes into ac-
count the number of people who are
candidates for an activity, as well as the
amount of beneﬁt per candidate. The lat-
ter measures only the amount of beneﬁt
per candidate. A case in point is LDL cho-
lesterolcontrolinpeoplewithestablished
CAD. The beneﬁts of treatment of indi-
viduals with CAD who have LDL choles-
terol 100 mg/dl are the largest of all the
prevention activities (an absolute reduc-
tion of MI risk of 40%). However, for the
population as a whole, this activity ranks
7th in terms of the number of MIs pre-
vented. Although the per-person beneﬁts
are large, only a small proportion
(1.6%) of the population is a candidate
for this activity.
Seventh, for the purposes of reducing
the costs of the prevention activities, the
most important component is the cost of
the interventions themselves: the drugs,
weight loss programs, and smoking ces-
sation programs. If ways could be found
to reduce the costs of the interventions,
overall costs could be reduced and value
could be increased to reach more accept-
able levels (Table 7).
All of these conclusions are very ro-
bust to a wide range of assumptions (Ta-
ble 6). However, as with any cost-
effectiveness analysis or clinical trial, the
speciﬁc results in the tables should be
considered only approximate, for several
reasons.First,becauseriskfactors,behav-
iors, practice protocols, performance lev-
els, and costs vary widely across the
country, there is no single set of results
that will be accurate in every setting. Sec-
ond, behaviors, tests, treatments, and
other factors will inevitably change in
ways that cannot be predicted today.
Third, actual practices will deviate from
the scenarios we have analyzed. For ex-
ample, while we analyzed the effect of
treating a variable to the goal speciﬁed in
national guidelines, some people will be
treated to lower levels, while others will
not reach the speciﬁed goals. Fourth,
some prevention activities have effects
that go beyond the boundaries of our
analysis. For example, we did not include
nonmedical costs such as lost productiv-
ity and absenteeism, nor do our estimates
of savings and effectiveness include the
effectsofthepreventionactivitiesonnon-
CVD and nondiabetes outcomes, such as
the effects of smoking on cancer. Fifth,
there is some degree of uncertainty when
risk factors are modiﬁed in either a real or
simulated clinical trial. There is further
uncertaintywhenonecarriesthemoutfor
30 years. However, we have based the ef-
fects of modifying risk factors on the data
available in the literature on both natural
history and from therapeutic trials. We
would hope that our ability to have more
cost-effective therapies will improve in
the future.
Last, we did not consider the costs
associated with screening to detect indi-
Table 7—Annual cost of prevention activities required to achieve various levels of cost/QALY
Cost/QALY
$0 $10,000 $20,000 $30,000 $40,000 $50,000
Aspirin to high-risk individuals $13 $262 $511 $760 $1,009 $1,258
BMI 30 kg/m
2 $219 $855 $1,491 $2,127 $2,763 $3,399
Blood pressure 140/90 mmHg in nondiabetic
individuals
$136 $379 $622 $865 $1,108 $1,351
CAD: LDL cholesterol 100 mg/dl $32 $144 $321 $498 $674 $851
Diabetes: blood pressure 130/80 mmHg $416 $1,518 $2,621 $3,724 $4,826 $5,929
Diabetes: A1C 7% $157 $361 $565 $770 $974 $1,178
Diabetes: LDL cholesterol 100 mg/dl $29 $268 $507 $746 $985 $1,224
High-risk CAD: LDL cholesterol 130 mg/dl $9 $239 $469 $699 $929 $1,159
Low-risk CAD: LDL cholesterol 160 mg/dl $125 $191 $257 $323 $390 —
Pre-diabetes: FPG 110 mg/dl $147 $409 $671 $933 $1,195 $1,457
Smoking: stop $971 $3,896 $6,821 $9,746 $12,671 $15,596
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for some of the prevention services stud-
ied (e.g., those in people with diabetes),
monitoringisroutineandthereisnoneed
for additional testing. For the others,
screening adds costs, but since such test-
ing occurs infrequently (i.e., every 3–5
years), the associated costs are not likely to
change the relative value of prevention
services. Moreover, if screening is bundled
at a single ofﬁce visit (e.g., lipid proﬁle,
blood pressure measurement, weight,
andsmokingstatus),theoverallimpactof
screening is likely to be negligible.
To our knowledge, only one other
study, conducted by the National Com-
mission on Prevention Priorities (NCCP),
has tried to analyze a broad range of pre-
vention activities (44). In that study, each
activity was assigned 1–5 points on each
of two measures—clinically preventable
burdenofdiseaseandcosteffectiveness—
for a total score ranging from 2 to 10. The
studyalsofoundthatforCVDprevention,
smoking cessation and aspirin received
high scores. However, our analysis differs
in many ways: we report the actual num-
ber of people who are candidates for each
activity, the effects of each activity one by
oneandincombination,andthenumbers
of CVD events, costs, and cost per QALY.
Other differences are that our analysis is
based on a single integrated model and
consistent methodology that includes a
representative sample of the U.S. popu-
lation, current use of prevention acti-
vities, representative costs, the recom-
mended treatment goals for prevention
activities, and a comprehensive sensi-
tivity analysis. The NCCP’s analysis was
based on the results of cost-effective-
ness analyses done separately for each
of the prevention activities. Each of the
analyses was done by different investi-
gators, using different models, different
sets of assumptions, and different pop-
ulations. None of the populations was a
representative sample of the U.S. popu-
lation,andnoneofthetreatmentsinthe
analyses precisely matched the recom-
mended prevention activities.
In summary, approximately three-
fourths of U.S. adults would beneﬁt from
at least one recommended prevention ac-
tivitytoreducetheincidenceofCVD.Full
deployment of these interventions could
potentially prevent approximately two-
thirds of MIs and one-third of strokes.
However, as they are currently delivered,
most of the interventions will substan-
tiallyincreasecosts.Ifourhealthcaresys-
tem were able to reduce the cost of
prevention activities, then the full poten-
tialforreducingtheburdenofCVDcould
be realized.
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